Showing 3471-3480 of 3844 results for "".
- Music City SCALE: Registration Open; New Website Launcheshttps://practicaldermatology.com/news/music-city-scale-registration-open-new-website-launches/2457564/Registration is now open for Music City Scale on the meeting's newly redesigned website. The website features new details about the meeting, scheduled May 9-11, 2019
- AlmirallShare Issues Call for Proposalshttps://practicaldermatology.com/news/almirallshare-issues-call-for-proposals/2457571/Almirall is seeking to find novel targets and concepts in the treatment of dermatological diseases. The company’s AlmirallShare open innovation platform is calling for proposals from October 10, 2018 to February 28, 2019 from universities, research centers, start-ups, biotechs and phar
- Topix Pharmaceuticals Introduces Its New Backbar Linehttps://practicaldermatology.com/news/topix-pharmaceuticals-introduces-its-new-backbar-line/2457572/Topix Pharmaceuticals, Inc. is rolling out its Backbar Line, a collection of 10 professional products that allows physicians to use their own branding. Only available for sale direct to office, the line is designed to support procedures and non-i
- ISDIN Launches Melatonik Nighttime Serumhttps://practicaldermatology.com/news/isdin-launches-melatonik-nighttime-serum/2457577/ISDIN's Melatonik nighttime serum formulated with melatonin, bakuchiol (a natural antioxidant with retinol-like properties) and Vitamin C, is now available. It was developed to help skin recover from the day and prepare it to fi
- Veloce BioPharma Announces Positive Phase 2b Study Results for VBP-926 for Chemotherapy-Associated Paronychiahttps://practicaldermatology.com/news/veloce-biopharma-announces-positive-phase-2b-study-results-for-vbp-926-for-chemotherapy-associated-paronychia/2457580/Veloce BioPharma, LLC, a clinical-stage biopharmaceutical company dedicated to developing topical therapeutics for unmet needs in dermatologic and ophthalmic diseases, shared positive results of its Phase 2b study of dilute povidone-iodine in a novel DMSO solvent system for the topical treatment
- Seysara: Oral Antibiotic is First Approved for Dermatology in 40 Yearshttps://practicaldermatology.com/news/seysara-oral-antibiotic-is-first-approved-for-dermatology-in-40-years/2457584/Seysara (sarecycline), a new, first in class tetracycline-derived oral antibiotic, is now approved for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Almirall, which recently acquired Seysara from Allergan, plans to laun
- Is Teen Acne a Sign of Future Financial Success?https://practicaldermatology.com/news/is-teen-acne-a-sign-of-future-financial-success/2457586/The love of books, the need for glasses and high intelligence are traits found among the top earners in many fields across the country, and now, a Ball State University researcher suggests that teen acne may also be on this list. In his study, “
- LEO Science & Tech Hub and Epicore Biosystems to Explore Wearable Skin Sensors to Improve Dermatologic Treatment Regimenshttps://practicaldermatology.com/news/leo-science-tech-hub-and-epicore-biosystems-to-explore-wearable-skin-sensors-to-improve-dermatologic-treatment-regimens/2457583/LEO Science & Tech Hub has established a new partnership with Epicore Biosystems focused on exploring the use of a non-invasive, wearable sweat sensor to measure prognostic biomarkers in real time, monitor patient response and inform treatment decisions. The initial project will inc
- FDA Approves Regeneron's Libtayo, First Treatment for Metastatic or Locally Advanced SCChttps://practicaldermatology.com/news/fda-approves-regenerons-libtayo-first-treatment-for-metastatic-or-locally-advanced-scc/2457589/Libtayo (cemiplimab-rwlc) injection (Regeneron Pharmaceuticals, Inc.) is now FDA-approved for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiatio
- RealSelf Survey: More than 1 in 3 US Adults are Considering Nips/Tuckshttps://practicaldermatology.com/news/realself-survey-more-than-1-in-3-us-adults-are-considering-nipstucks/2457591/One in three adults (37 percent) in the US are considering at least one cosmetic treatment in the next 12 months, with significantly more considering nonsurgical procedures (34 percent) than surgical ones (24 percent), according to the